Published in Toxins (Basel) on February 29, 2016
Pharmacotherapy for Pediatric Neurogenic Bladder. Paediatr Drugs (2017) 0.75
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn (2002) 22.80
Prevalence and burden of overactive bladder in the United States. World J Urol (2002) 7.33
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol (2006) 7.13
SV2 is the protein receptor for botulinum neurotoxin A. Science (2006) 4.51
The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol (2008) 4.51
Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol (2014) 2.86
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol (2010) 2.68
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol (2005) 2.68
Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol (2000) 2.66
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol (2011) 2.37
Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol (2011) 2.35
Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol (2007) 2.32
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol (2012) 2.29
Prevalence and co-occurrence of pelvic floor disorders in community-dwelling women. Obstet Gynecol (2008) 2.05
EAU guidelines on surgical treatment of urinary incontinence. Eur Urol (2012) 2.05
Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol (2007) 2.04
Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol (2008) 1.96
Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol (2012) 1.88
Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol (2005) 1.86
Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol (2008) 1.85
Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology (2004) 1.67
The role of the human bladder lamina propria myofibroblast. BJU Int (2003) 1.57
Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol (2007) 1.57
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol (2012) 1.46
Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol (2013) 1.42
Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol (2005) 1.25
Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache (2003) 1.22
Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol (2009) 1.22
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol (2015) 1.20
Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol (2006) 1.15
Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol (2004) 1.12
Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol (2011) 1.11
P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol (2004) 1.10
Activation of neurokinin 1 receptors on interstitial cells of Cajal of the guinea-pig small intestine by substance P. Histochem Cell Biol (1998) 1.08
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn (2011) 1.06
Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn (2011) 1.04
Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest (1997) 1.01
Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules (2010) 0.95
Urodynamic detrusor overactivity in patients with overactive bladder symptoms. Int Neurourol J (2011) 0.90
Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology (2005) 0.86
Clinical impact of overactive bladder. Rev Urol (2002) 0.85
Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center. Neurourol Urodyn (2015) 0.81
Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events. Int Urogynecol J (2014) 0.80
Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J (Engl) (2015) 0.79
The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis. Neurourol Urodyn (2014) 0.79
Retrograde transport of radiolabelled botulinum neurotoxin type A to the CNS after intradetrusor injection in rats. BJU Int (2015) 0.79
Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder. Urol Nurs (2014) 0.78
The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial. Int J Clin Pract (2011) 0.76